Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered

The Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge on Wednesday, July 1, 2026, opening a short-term demonstration that gives eligible Medicare Part D beneficiaries access to selected GLP-1 weight-loss medications for a flat $50 monthly copayment through December 31, 2027. The program covers Novo Nordisk A/S’s Wegovy in both injection and tablet formulations, Eli Lilly and Company’s Foundayo oral orforglipron tablets, and Eli Lilly’s Zepbound in the KwikPen configuration only, while explicitly excluding the Zepbound single-dose pen, Zepbound vials, Ozempic, Mounjaro and Rybelsus. The Kaiser Family Foundation has estimated that approximately 3.8 million Part D beneficiaries meet the clinical criteria based on 2023 enrollment data, representing 8 percent of the 47.5 million-member Part D pool and creating the largest single-event demand shock the GLP-1 category has absorbed since the initial commercial launches. Eligible beneficiaries must have a body mass index of 35 or higher, a BMI of 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease, or a BMI of 27 or higher with pre-diabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease, and prior authorization is submitted directly to a single CMS central processor rather than routed through Part D plan sponsors. The Bridge is architecturally distinct from every prior CMS weight-loss coverage decision because it operates outside the Part D benefit flow, meaning Part D plan sponsors carry no financial risk and the $50 copay does not count toward beneficiary deductibles or the $2,100 annual out-of-pocket maximum for 2026.

What does the covered-drug list tell us about how CMS deliberately balanced Novo Nordisk and Eli Lilly?

The specific inclusion and exclusion pattern is the most strategically revealing element of the program design. Novo Nordisk secures both an injection (Wegovy 2.4 mg) and an oral tablet (Wegovy 25 mg semaglutide) in the covered list, giving the Danish manufacturer parity of formulation options within the program. Eli Lilly secures the Zepbound KwikPen and Foundayo, its oral orforglipron approved April 1, 2026 under the FDA’s expedited National Priority Voucher pilot, producing the same one-injection-one-oral structure. The result is a program that neither manufacturer can dominate purely on formulation availability, which forces price and clinical differentiation into the foreground while both companies capture meaningful Medicare volume.

The deliberate exclusion of Ozempic, Mounjaro and Rybelsus is where the strategic logic sharpens. Those three products are approved and marketed for type 2 diabetes and, in Ozempic’s case, cardiovascular risk reduction, and they continue to be covered through the standard Part D benefit for those indications. Including them under the weight-loss Bridge would have created cross-indication pricing arbitrage, because Ozempic is a substantially higher-priced sibling product to Wegovy that would have compressed Bridge economics if manufacturers had been forced to accept the $50 copay economics on Ozempic prescriptions written primarily for weight loss. The exclusion preserves the diabetes revenue franchise for both Novo Nordisk and Eli Lilly while directing Bridge demand to the specifically weight-loss-approved formulations.

The Zepbound KwikPen carve-out is the subtle detail worth flagging. Eli Lilly’s Zepbound single-dose pen and vials remain outside the Bridge, and the KwikPen inclusion is the multi-dose reusable auto-injector format that has been Eli Lilly’s preferred commercial packaging since launch. The exclusion of the single-dose pen and vials effectively steers Medicare Bridge volume into a specific packaging that Eli Lilly’s manufacturing footprint can scale, which is consistent with the company’s public commentary about production capacity expansion at Foundayo and Zepbound facilities. Novo Nordisk faces no equivalent packaging restriction on Wegovy, giving Novo Nordisk marginal execution flexibility on Bridge fulfilment.

What does the 3.8 million eligible beneficiary estimate actually translate to in commercial reality?

The KFF estimate of 3.8 million eligible beneficiaries frames the upper bound of potential Bridge enrolment, but actual utilisation will lag that estimate materially through 2026 due to prior authorisation friction, physician awareness gaps and pharmacy fulfilment infrastructure limitations. The CMS single central processor requires physicians to submit prior authorisation directly rather than through their existing Part D plan portals, which is a process most primary care physicians and endocrinologists have never used before. Anecdotal reporting from patient advocacy groups indicates significant physician confusion about submission procedures, BIN and PCN codes for pharmacies, and clinical criteria documentation.

A realistic 2026 uptake estimate suggests approximately 500,000 to 800,000 Bridge enrolees by the end of the calendar year, ramping to potentially 1.5 to 2.0 million by the end of 2027 as the physician learning curve resolves and pharmacy fulfilment stabilises. Even at those subdued penetration rates, the incremental Medicare-covered GLP-1 volume represents a step-change in the demand curve for both Novo Nordisk and Eli Lilly relative to their prior Medicare exposure. The strategic significance is that this is the first time GLP-1 weight-loss medications have moved into predictable government-payer volume at scale in the United States, which changes both the demand forecasting and manufacturing capacity planning for both companies.

The demographic segmentation of the eligible population also matters commercially. Medicare Part D beneficiaries skew older, and the BMI-plus-comorbidity clinical criteria mean that the Bridge population is disproportionately weighted toward beneficiaries with cardiometabolic risk factors that make GLP-1 therapy clinically indicated. That is a durable customer cohort with high compliance likelihood relative to younger cash-pay users, which supports steady long-run refill economics. Both manufacturers have been signalling in investor communications that Medicare volume is a strategic priority precisely because the compliance and repeat-fill dynamics improve the net present value of Bridge revenue relative to spot cash-pay volume from telehealth channels.

Why does the exclusion of Ozempic, Mounjaro and Zepbound single-dose pens matter more than the inclusions?

The exclusions function as guard rails against a series of arbitrage and access dynamics that would have compromised both manufacturer economics and CMS budget discipline. Ozempic and Mounjaro remain covered under standard Part D for their approved diabetes indications, and any inclusion under the weight-loss Bridge would have created dual-pathway coverage that would rapidly become the preferred physician prescribing route because the $50 copay is far more attractive to patients than standard Part D cost-sharing. That dynamic would have compressed diabetes-indication revenue for both manufacturers through indication shifting, and CMS avoided the problem by keeping the two coverage pools cleanly separated.

The Rybelsus exclusion, and by extension the reformulated Ozempic Pill that replaces it in the United States market, follows the same logic on the oral side. Rybelsus is Novo Nordisk’s oral semaglutide originally approved in 2019 for type 2 diabetes at doses of 3, 7 and 14 mg, and the recent reformulation as Ozempic Pill at 1.5, 4 and 9 mg preserves the diabetes-only indication in the United States. The Bridge instead covers Wegovy in tablet form at 25 mg, which is the weight-loss-approved oral semaglutide dose. That formulation-specific distinction preserves the diabetes franchise while giving Novo Nordisk the oral weight-loss opportunity that the Wegovy pill represents.

Zepbound single-dose pen and vial exclusion produces the second-order manufacturing steering. The KwikPen is a reusable auto-injector that dispenses multiple doses from a single device, and directing Medicare Bridge volume into KwikPen configuration reduces the unit-of-device economics for Eli Lilly relative to single-dose alternatives. That subtly improves Eli Lilly’s gross margin on Bridge fulfilment even though the manufacturer accepts the $50 patient copay economics. The exclusion also aligns with Eli Lilly’s public commentary about auto-injector production capacity, which has scaled more rapidly than single-dose device manufacturing at facilities in Indiana and North Carolina.

What are the manufacturer economics of a $50 copay program running outside the Part D benefit flow?

The financial architecture of the Bridge is more favourable to manufacturers than the retail $50 copay implies. Because the program operates outside the Part D benefit flow through a single CMS central processor, plan sponsors are not carrying risk and the standard Part D discount and rebate mechanics do not apply. The net price that Novo Nordisk and Eli Lilly ultimately receive is a matter of confidential negotiation with CMS through the Bridge structure, and the disclosed information indicates that both manufacturers accepted commercially acceptable net pricing to secure inclusion in the covered drug list. That is materially different from the deeply discounted net prices that Part D negotiated rates produce for many high-cost drugs, and it preserves stronger unit economics for both companies.

Wholesale acquisition costs for the covered products provide the baseline reference. Wegovy tablets carry a WAC of $1,349 per month, Foundayo pricing through LillyDirect starts at $149 per month for the lowest dose and rises to $299 for maintenance doses, and Zepbound KwikPen commercial pricing has been in a similar range depending on dose and channel. The $50 patient copay is a fraction of the manufacturer net price that CMS is effectively paying, which means the Bridge represents a substantial government revenue transfer to both manufacturers even after accepting rebate concessions. Investors should not read the $50 headline as indicative of manufacturer economics, and analyst models should assume net prices to Novo and Lilly in the several-hundred-dollar range per Bridge prescription depending on formulation.

The manufacturing capacity implications are the operational counterpart to the pricing story. Both companies have been investing aggressively in production capacity, with Eli Lilly building substantial orforglipron and tirzepatide capacity in Indiana and North Carolina and Novo Nordisk expanding semaglutide production in Denmark, North Carolina and via the Catalent acquisition. Bridge volume is additive to existing commercial demand, and the incremental capacity utilisation improves gross margin economics for both manufacturers relative to running at partial capacity. That is a positive operating leverage story that should support gross margin performance through 2026 and 2027 for both companies.

How does the Bridge reshape the competitive dynamic against Hims and Hers, Ro, cash-pay clinics and the compounding pharmacy shadow market?

The cash-pay GLP-1 market that developed during 2023 to 2025 in response to GLP-1 shortages and off-label demand faces a structural setback from the Bridge launch. Hims and Hers Health Inc. (NYSE: HIMS), Ro, and various telehealth platforms have been generating substantial revenue from cash-pay GLP-1 prescriptions, including from compounded semaglutide and tirzepatide during the drug shortage period. As Medicare beneficiaries migrate to the $50 Bridge copay for weight-loss GLP-1s, and as commercial payers respond to the political pressure the Bridge creates for parallel employer-plan coverage, the cash-pay demand pool that has supported telehealth growth compresses materially.

The compounding pharmacy shadow market faces a specific regulatory and commercial squeeze. FDA declared the tirzepatide and semaglutide shortages resolved in late 2024 and 2025 respectively, and compounding pharmacies that had been producing personalised compounded GLP-1s under Section 503A and 503B pathways are now facing enforcement risk. The Bridge launch adds economic pressure by reducing the price premium that compounded products can command against branded GLP-1s available for $50 per month to a substantial Medicare cohort. The combination of regulatory enforcement and reduced pricing spread compresses the compounding pharmacy opportunity through 2026 and 2027.

Weight Watchers International Inc., which has pivoted to become a GLP-1 telehealth prescriber and coach through its Sequence acquisition, faces mixed dynamics. Bridge access reduces the cash-pay opportunity for Medicare-age subscribers but increases the underlying population interested in GLP-1 therapy generally, which could support the coaching and behavioural adherence programme that Weight Watchers offers alongside prescription access. Investors in the weight management platform names should model a competitive rebalancing rather than pure disruption, because the demand-side expansion partially offsets the pricing-side compression.

What data collection subtext is CMS actually running through the Bridge and how does the BALANCE Model connect?

The Bridge is not primarily an access program, and treating it as such misses the strategic subtext. CMS is running the Bridge partly as a large-scale utilisation and cost-effectiveness data collection exercise to inform future Part D pricing negotiations under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The single central processor architecture collects granular prescription, adherence, weight outcome and downstream medical utilisation data that CMS can use to build a defensible pricing negotiation position when Wegovy, Ozempic, Zepbound, Mounjaro and Foundayo become eligible for future negotiation cycles.

The BALANCE Model connection is where the longer-term strategic significance sits. BALANCE, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, was originally scheduled to run in Medicare Part D from 2027 through 2031 with comprehensive GLP-1 access alongside lifestyle intervention. CMS indefinitely postponed the Part D component of BALANCE in April 2026 and extended the Bridge by a year to fill the coverage gap. The rationale for postponing BALANCE while running the Bridge is that CMS needs the utilisation data the Bridge will generate to structure BALANCE pricing and coverage rules on a more informed empirical basis.

The manufacturer negotiating position for future Part D price negotiations is materially different depending on Bridge outcomes. If Bridge data demonstrates significant downstream medical cost reduction through weight loss, cardiovascular event avoidance and diabetes progression prevention, both Novo Nordisk and Eli Lilly can argue for premium pricing that reflects the total healthcare cost offset. If Bridge data shows lower-than-expected adherence, high discontinuation rates or modest real-world weight outcomes compared with clinical trial results, CMS will have empirical basis for more aggressive price negotiation. Both manufacturers are effectively co-designing the data that will constrain their own future pricing power, which is a nuanced strategic trade-off that has not been fully priced into consensus expectations.

Key takeaways on what the Medicare GLP-1 Bridge means for Novo Nordisk, Eli Lilly, telehealth GLP-1 platforms and the future of Part D negotiations

• The Medicare GLP-1 Bridge launched on July 1, 2026 at a flat $50 monthly copay for eligible Part D beneficiaries, running through December 31, 2027 with an estimated 3.8 million eligible beneficiaries based on Kaiser Family Foundation analysis.
• The covered drug list is deliberately balanced between Novo Nordisk (Wegovy injection and tablet) and Eli Lilly (Foundayo tablet and Zepbound KwikPen only), with Ozempic, Mounjaro and Rybelsus explicitly excluded to preserve the diabetes indication revenue franchise.
• The program operates outside the Part D benefit flow through a single CMS central processor, so Part D plan sponsors carry no risk and standard rebate mechanics do not apply, preserving stronger unit economics for both manufacturers than a standard Part D coverage decision would have produced.
• Actual 2026 uptake will lag the 3.8 million eligible ceiling due to prior authorisation friction, physician awareness gaps and pharmacy fulfilment infrastructure that has not previously routed through the CMS central processor.
• Wholesale acquisition costs for Wegovy tablets at $1,349 per month and Foundayo up to $299 per month indicate that the $50 patient copay masks substantially higher net manufacturer revenue paid by CMS through the Bridge architecture.
• The Zepbound KwikPen-only inclusion steers Medicare volume into Eli Lilly’s preferred reusable auto-injector packaging, providing marginal gross margin benefit relative to single-dose device fulfilment.
• Hims and Hers Health, Ro, telehealth cash-pay GLP-1 platforms and compounding pharmacies face structural demand compression as Medicare-age beneficiaries migrate to Bridge access.
• Weight Watchers International faces a rebalancing between cash-pay compression and expanded population interest in GLP-1 therapy, which may support continued relevance of the behavioural coaching component.
• The Bridge doubles as a large-scale utilisation and cost-effectiveness data collection exercise that will inform future Part D price negotiation positions for both manufacturers under the Inflation Reduction Act framework.
• The BALANCE Model launching in Medicare Part D remains indefinitely delayed, with CMS extending the Bridge by a year specifically to collect the empirical data needed to structure BALANCE pricing and coverage rules on a more informed basis.